Survodutide
GLP-1 / glucagon dual receptor agonist (BI 456906)
Overview
Survodutide, carrying the development code BI 456906, is an investigational dual co-agonist hitting the GLP-1 and glucagon receptors. The clinical-development program runs through a Boehringer Ingelheim / Zealand Pharma partnership and is in Phase 3 for both chronic weight management and metabolic-liver indications, MASH (metabolic-associated steatohepatitis) chief among them. Receptor coverage maps to GLP-1R plus GCGR with no GIP arm, mirroring Mazdutide and contrasting with the GIP-containing dual / tri-agonist class. That positioning makes the molecule useful in two distinct ways: as a research tool for studying glucagon-pathway pharmacology isolated from GIP signalling, and as a clinical asset for indications where glucagon-mediated hepatic energy expenditure delivers therapeutic value. For research-lab buyers, Vialdyne releases Survodutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The catalogue 10 mg fill covers bench-scale aliquot work in the typical research context. The release packet leans particularly hard on ESI-MS identity confirmation, the structural proximity to other GLP-1 / glucagon dual co-agonists means catalogue-level cross-supplier confusion is an operationally real failure mode, and LC-MS/MS sequence verification is the recommended add-on for any first-time procurement to lock in positive identity before the lot enters the QA file.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- 2365457-03-9
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 10 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec identity (ESI-MS)
- Counter-ion / residual solvent
- Bacterial endotoxin (LAL, USP <85>)
- Microbial limits (USP <61>/<62>)
- Stability data on request
- 503A / 503B documentation support
Regulatory note
Investigational compound in Phase 3 development (Boehringer Ingelheim / Zealand Pharma); not approved as a finished drug. Supplied for research use only. CAS commonly cited but should be verified per batch COA.
Frequently asked questions
What's the difference between Survodutide and Mazdutide?▾
Both are dual GLP-1 / glucagon receptor co-agonists in Phase 3 development, both lack a GIP arm, and both are therefore mechanistically distinct from Tirzepatide (GIP+GLP-1) and Retatrutide (GIP+GLP-1+glucagon). What separates them at the molecule level is sequence and lipidation chemistry; at the receptor-pharmacology level they are similar enough to be treated as parallel rather than interchangeable. The development context diverges too: Mazdutide targets chronic weight management and type 2 diabetes through Innovent / Eli Lilly's China-focused program, while Survodutide pursues both weight management and metabolic-liver indications (MASH) through Boehringer Ingelheim / Zealand Pharma. Verify exact identity per batch COA before treating the two as substitutable in any research context.
Why is Survodutide also being developed for MASH (metabolic-associated steatohepatitis) on top of weight management?▾
Because the glucagon-receptor arm of a dual GLP-1 / glucagon co-agonist produces direct hepatic energy expenditure effects, which translate to reduced hepatic steatosis (fat accumulation in the liver) and reduced hepatic inflammation in metabolic-liver models. MASH is the inflammatory progression of NAFLD, characterised by both steatosis and inflammation, and addressing both arms requires a mechanism that goes beyond the incretin-axis-only effects of GIP/GLP-1 agonists like Tirzepatide. Survodutide's Phase 2 MASH data (the LIVE-1 study, published 2024) supported the Phase 3 program expansion into the MASH indication alongside the more conventional weight-management endpoints, which makes the molecule useful as a research tool for any model that touches both metabolic and hepatic endpoints in the same animal.
What's Boehringer Ingelheim and Zealand Pharma's role in Survodutide development?▾
The molecule originated on Zealand Pharma's peptide-engineering platform, which has produced multiple commercially relevant peptides. Zealand out-licensed Survodutide to Boehringer Ingelheim, who is now leading the global Phase 3 development program. This origin and licensing arrangement distinguishes Survodutide commercially from Mazdutide (Innovent / Eli Lilly partnership, China-focused) and from the Lilly internal pipeline (Tirzepatide, Retatrutide). For research procurement, the development-partner identity doesn't change the bulk material released, what matters operationally is matching the specific molecule sourced to the clinical-data reference your work needs to align with.
Related peptides